Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Genitourinary 1CNS 1

Conditions

Advanced Non-small Cell Lung Cancer 1

Interventions

Carboplatin 1145Cisplatin 874Pemetrexed 832pembrolizumab 604Paclitaxel 597Docetaxel 535Gemcitabine 424Radiotherapy 374Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 294durvalumab 254Drug Therapy 233osimertinib 217atezolizumab 207Radiosurgery 188Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 123Magnetic Resonance Spectroscopy 120Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × rofecoxib × Thoracic × Clear all
NCT00385606 2023-03-23

Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC

National Cancer Institute, Naples

Phase 2/3 Completed
400 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡